Dr Sue Manley studied Biochemistry at Queen’s University Belfast and obtained PhD from Bristol University working with Professor Sir Philip Randle on insulin secretion. She was appointed biochemist for UK Prospective Diabetes Study, the clinical trial into Type 2 diabetes, based at Oxford University. She was responsible for ensuring equivalence of HbA1c to US trial into Type 1 diabetes. She became a member of US National Glycated Hemoglobin Standardization Program advisory committee and was awarded FRCPath based on published papers. She moved to University Hospitals Birmingham as a clinical scientist and belongs to Joint British Diabetes Societies inpatient committee. She initiated Diabetes Translational Research Group and given diabetes pandemic, guidance is being written on HbA1c and fructosamine with inner-city GPs.